TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06170944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
Study: NCT06383026

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Screening
Description: Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.

Intervention type: OTHER
Intervention: Survey/Interview
Description: A mixed-methods approach including electronic surveys and one on one interviews.

Intervention type: OTHER
Intervention: Focus Group
Description: A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for transgendered and nonbinary persons.
Study: NCT06008210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Intervention
Description: The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
Study: NCT06424561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention Group
Description: The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers.
Study: NCT04875910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week.
Study: NCT05710900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
Study: NCT05681013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: The effect of the Laughter Therapy on nursing students
Study: NCT05183334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: PD5I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: PD5I

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 100 MG
Description: opiod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 100 MG
Description: opiod
Study: NCT05850702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: inhale 5ml of 2% lidocaine by nebulization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: inhale 5ml of saline by nebulization
Study: NCT05704855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise + Behavioural Counselling
Description: The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
Study: NCT06431945

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C antibody (anti-HCV) test
Description: Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C RNA test and genotype test
Description: RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
Study: NCT05640063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Delivery and Newborn kit
Description: Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
Study: NCT05136677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study: NCT05411835

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Ketone Supplement
Description: Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Isocaloric Placebo Supplement
Description: Maltodextrin with flavors and stevia sweetener
Study: NCT06285890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: Given by PO
Study: NCT04991857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-FAME-HF
Description: 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group - HF education program
Description: For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
Study: NCT06235983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.
Study: NCT05664737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05906628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06257888

Intervention type: OTHER
Intervention: patient navigation
Description: two trained patient navigators will admit breast cancer patients to HCM, navigate them from admission to commencement of first treatment and will collect all pertinent epidemiological data and variables
Study: NCT05200377

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Patients recruited will receive Magnetic resonance imaging.
Study: NCT06455852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oral cholera vaccine or typhoid conjugate vaccine
Description: One group will receive a 2 dose oral cholera vaccine, the other a typhoid conjugate vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: oral cholera vaccine or typhoid conjugate vaccine
Description: One group will receive a 2 dose oral cholera vaccine, the other a typhoid conjugate vaccine
Study: NCT05105672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: Undergo pelvic EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: brachytherapy
Study: NCT06090968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: 20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: clamping the umbilical cord as soon as possible (average 30 seconds)
Study: NCT05403086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
Study: NCT06381466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0233
Description: Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD0233 Placebo
Description: Randomized participants will receive matching placebo orally as a SAD or MAD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD0233 Placebo
Description: Randomized participants will receive matching placebo orally as a SAD or MAD.
Study: NCT05730621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate Sustained Release/Aspirin
Description: Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd for 12 weeks
Study: NCT05211895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (Intravenous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab IV (Intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab IV (Intravenous infusion)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo IV (Intravenous infusion)
Study: NCT06194188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of CU-20401
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of CU-20401
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous injection of CU-20401
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
Study: NCT04763200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®
Description: Impella CP / Impella CP with SmartAssist will be used in most patients randomized to the Impella arm. Impella 2.5 may be used in patients with small body size (BMI \<20 kg/m2 or body weight \<60 kg) or if the iliofemoral vasculature is able to accommodate the smaller Impella 2.5 device but not the Impella CP device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IABP Intra-aortic balloon pump
Description: IABP uses counterpulsation to provide 0.2L/min coronary flow
Study: NCT05766943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Pass ON
Description: Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smart Pass OFF
Description: Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
Study: NCT05514054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Administered per local approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Administered per local approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Administered per local approved label.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered per local approved label.
Study: NCT04785092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: All Autologous Cartilage Regeneration
Description: All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
Study: NCT05993546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum assisted sheath
Description: allows for simultaneous suction with continuous irrigation throughout the case to enhance visibility and facilitate stone retrieval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive suction via conventional sheath
Description: conventional access sheath for stone retrieval using current technique via passive suction
Study: NCT04937387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI
Description: FF/VI will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI
Description: FF/VI will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.
Study: NCT04643041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watch and wait
Description: patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
Study: NCT05044247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP blocks
Description: ultrasound and fluoroscopy to identify the spread of drug
Study: NCT05545423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrumented assisted soft tissue mobilization
Description: the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises